查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417546

地中海贫血治疗市场报告：2030 年趋势、预测与竞争分析

Thalassemia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

地中海贫血治疗的趋势和预测

2030年，全球地中海贫血治疗市场预计将达到122亿美元，2024年至2030年的复合年增长率为5.1%。该市场的主要驱动因素是地中海贫血盛行率的增加、正在开发的地中海贫血疗法数量的增加以及药物研发和医疗保健成本的增加。全球地中海贫血治疗市场的未来充满希望，医院/诊所和诊断实验室市场充满机会。

地中海贫血治疗市场洞察

Lucintel 预测，由于彻底血液筛检的风险较低，输血将在预测期内达到最高成长。

由于人们对地中海贫血的认识不断提高以及政府试图鼓励基因治疗，北美在预测期内仍将是最大的地区。

常问问题

Q1.市场规模有多大？

A1. 到 2030 年，全球地中海贫血治疗市场预计将达到 122 亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，全球地中海贫血治疗市场预计将以5.1%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动力是地中海贫血盛行率的增加、正在开发的地中海贫血药物数量的增加以及药物研发和医疗保健成本的增加。

Q4.市场的主要细分市场是什么？

A4. 全球地中海贫血治疗市场的未来看起来充满希望，医院/诊所和诊断实验室市场存在机会。

Q5.市场上主要企业有哪些？

A5. 主要的地中海贫血治疗公司如下。

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，由于彻底血液筛检的风险较低，输血将在预测期内出现最高成长。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于人们对地中海贫血的认识不断提高以及政府试图鼓励基因治疗，北美在预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球地中海贫血治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球地中海贫血治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球地中海贫血治疗市场
    • α地中海贫血
    • β地中海型贫血
  • 按治疗分類的全球地中海贫血治疗市场
    • 输血
    • 铁螯合疗法
    • 补充品叶酸
    • 基因治疗
    • 骨髓移植
  • 按最终用途分類的全球地中海贫血治疗市场
    • 医院和诊所
    • 诊断实验室
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球地中海贫血治疗市场（按地区）
  • 北美地中海贫血治疗市场
  • 欧洲地中海贫血治疗市场
  • 亚太地区地中海贫血治疗市场
  • 其他地区地中海贫血治疗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球地中海贫血治疗市场成长机会
    • 全球地中海贫血治疗市场成长机会（按治疗）
    • 全球地中海贫血治疗市场成长机会（依最终用途）
    • 全球地中海贫血治疗市场按地区成长机会
  • 全球地中海贫血治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球地中海贫血治疗市场的产能扩张
    • 全球地中海贫血治疗市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell
简介目录

Thalassemia Treatment Trends and Forecast

The future of the global thalassemia treatment market looks promising with opportunities in the hospital and clinic and diagnostic laboratory markets. The global thalassemia treatment market is expected to reach an estimated $12.2 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are the increased prevalence of thalassemia, growing number of thalassemia medications under development, as well as, growing costs for pharmaceutical research and development as well as for healthcare.

A more than 150-page report is developed to help in your business decisions.

Thalassemia Treatment by Segment

The study includes a forecast for the global thalassemia treatment by type, treatment, end use, and region.

Thalassemia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Alpha-Thalassemia
  • Beta Thalassemia

Thalassemia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Transfusions
  • Iron Chelation Therapy
  • Folic Acid Supplements
  • Gene Therapy
  • Bone Marrow Transplants

Thalassemia Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital and Clinics
  • Diagnostic Laboratories
  • Others

Thalassemia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Thalassemia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies thalassemia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the thalassemia treatment companies profiled in this report include-

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell

Thalassemia Treatment Market Insights

Lucintel forecasts that blood transfusions is expected to witness the highest growth over the forecast period due to the low risk resulting from meticulous blood screening.

North America will remain the largest region over the forecast period due to growing thalassemia awareness and government attempts to encourage gene treatment.

Features of the Global Thalassemia Treatment Market

Market Size Estimates: Thalassemia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Thalassemia treatment market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Thalassemia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, treatment, end use, and regions for the thalassemia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the thalassemia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the thalassemia treatment market size?

Answer: The global thalassemia treatment market is expected to reach an estimated $12.2 billion by 2030.

Q2. What is the growth forecast for thalassemia treatment market?

Answer: The global thalassemia treatment market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the thalassemia treatment market?

Answer: The major drivers for this market are the increased prevalence of thalassemia, growing number of thalassemia medications under development, as well as, growing costs for pharmaceutical research and development as well as for healthcare.

Q4. What are the major segments for thalassemia treatment market?

Answer: The future of the global thalassemia treatment market looks promising with opportunities in the hospital and clinic and diagnostic laboratory markets.

Q5. Who are the key thalassemia treatment market companies?

Answer: Some of the key thalassemia treatment companies are as follows.

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell

Q6. Which thalassemia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that blood transfusions is expected to witness the highest growth over the forecast period due to the low risk resulting from meticulous blood screening.

Q7. In thalassemia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing thalassemia awareness and government attempts to encourage gene treatment.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the thalassemia treatment market by type (alpha-thalassemia and beta thalassemia), treatment (blood transfusions, iron chelation therapy, folic acid supplements, gene therapy, and bone marrow transplants), end use (hospital and clinics, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Thalassemia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Thalassemia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Thalassemia Treatment Market by Type
    • 3.3.1: Alpha-thalassemia
    • 3.3.2: Beta Thalassemia
  • 3.4: Global Thalassemia Treatment Market by Treatment
    • 3.4.1: Blood Transfusions
    • 3.4.2: Iron Chelation Therapy
    • 3.4.3: Folic Acid Supplements
    • 3.4.4: Gene Therapy
    • 3.4.5: Bone Marrow Transplants
  • 3.5: Global Thalassemia Treatment Market by End Use
    • 3.5.1: Hospital and Clinics
    • 3.5.2: Diagnostic Laboratories
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Thalassemia Treatment Market by Region
  • 4.2: North American Thalassemia Treatment Market
    • 4.2.1: North American Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.2.2: North American Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others
  • 4.3: European Thalassemia Treatment Market
    • 4.3.1: European Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.3.2: European Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others
  • 4.4: APAC Thalassemia Treatment Market
    • 4.4.1: APAC Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.4.2: APAC Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others
  • 4.5: ROW Thalassemia Treatment Market
    • 4.5.1: ROW Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.5.2: ROW Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Thalassemia Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Thalassemia Treatment Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Thalassemia Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Thalassemia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Thalassemia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Thalassemia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Thalassemia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Bluebird Bio
  • 7.3: Kiadis Pharma
  • 7.4: CELGENE
  • 7.5: Sangamo Therapeutics
  • 7.6: Acceleron Pharma
  • 7.7: Gamida Cell